Literature DB >> 20508559

[Urokinase in the management of occluded PICC lines].

C Muller1, A Jacquier, A Varoquaux, F Cohen, G Louis, J Y Gaubert, G Moulin, J M Bartoli, V Vidal.   

Abstract

PURPOSE: To determine the efficacy and safety of urokinase in the management of occluded PICC lines.
MATERIALS AND METHODS: A total of 587 PICC lines were placed over an 11 month period. During this period, 28 PICC lines (4.8%) became occluded: 12 occluded PICC lines were successfully managed by simple flushing with normal saline while 16 PICC lines were thrombolyzed with urokinase.
RESULTS: After urokinase, 93.8% (15/16) of occluded PICC lines were completely patent. A single infusion of urokinase, 20,000 IU over 30 minutes, was used in all cases. No secondary occlusion or complication was noted after urokinase.
CONCLUSION: Urokinase is effective and safe to restore patency to occluded PICC lines. The procedure is simple, and could be performed at the bedside by nursing staff after medical prescription. It is an alternative to over the wire PICC line exchange, that could reduce the risk of complication related to manipulations, patient discomfort and cost.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20508559     DOI: 10.1016/s0221-0363(10)70040-8

Source DB:  PubMed          Journal:  J Radiol        ISSN: 0221-0363


  3 in total

1.  Practical considerations in the use of outpatient antimicrobial therapy for musculoskeletal infections.

Authors:  Camelia E Marculescu; Elie F Berbari; J Robert Cantey; Douglas R Osmon
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

Review 2.  Interventions for restoring patency of occluded central venous catheter lumens.

Authors:  Clare van Miert; Rebecca Hill; Leanne Jones
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

3.  The complete recanalization of PICC-related venous thrombosis in cancer patients: A series of case reports.

Authors:  Zuo-Ping Huang; Xing-Jing Liu; Bin-Xin Zou; Li-Gen Wang; Tao Zhou
Journal:  Exp Ther Med       Date:  2013-06-07       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.